Azitam

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azitam

Quick Facts

Property Description
Active ingredient Azithromycin (INN)
Forms Tablets, capsules, oral suspension
Pharmacological class Macrolide Antibiotic (Azalide subclass)
General purpose Combats susceptible bacterial infections
Origin Semisynthetic

What Type of Medicine is Azitam?

Azitam is the brand name for a medication whose sole active ingredient is Azithromycin. This drug is classified as a prescription-only systemic anti-infective, a status widely recognized by regulatory bodies globally. Azithromycin is chemically a semisynthetic macrolide antibiotic, belonging more precisely to the azalide subclass. This classification reflects a structural refinement, where the single-active ingredient compound is modified to enhance its stability and tissue absorption compared to older macrolides. Its unique chemical structure supports a prolonged presence in the body, which is a key differentiating feature of the azalide group.

Azithromycin’s Forms and General Purpose

The medication is supplied in several dosage forms intended for systemic administration, primarily including film-coated tablets and a powder for oral suspension. This range of forms allows flexibility for use across different patient groups, including pediatric patients who benefit from the liquid suspension. The general purpose of Azithromycin is to address infections caused by a broad-spectrum of bacteria, making it clinically recognized for its versatility in treating microbial proliferation. Its fundamental role is to halt the infectious process: it acts primarily as a bacteriostatic agent by inhibiting bacterial protein synthesis. This targeted action supports the body’s innate ability to clear the infection and facilitates patient recovery from bacterial illness.

What side effects are possible with Azitam?

Possible Side Effects and Safety Information

The safety profile of Azitam (Azithromycin) is officially classified by government regulatory authorities based on clinical experience, detailing both common reactions and serious, rare events. Adverse reactions are grouped by the specific organ system affected and the frequency of their occurrence, strictly as documented in the Summary of Product Characteristics (SmPC) and FDA labeling.


Frequency-Classified Adverse Reactions

The most frequently reported adverse effect is diarrhea, classified as Very Common (affecting ge 1 in 10 patients). Common effects (affecting up to 1 in 10) include headache, nausea, vomiting, and abdominal pain. Less common reactions fall under the Uncommon and Rare categories, which may involve neurological effects like dizziness or dermatological responses such as rash.


Serious Adverse Reactions

Official labeling emphasizes the risk of serious but rare events. These include potentially fatal cardiac rhythm abnormalities, specifically QT interval prolongation leading to Torsade de Pointes. Severe hypersensitivity reactions (e.g., Anaphylaxis, Stevens-Johnson Syndrome) and severe hepatotoxicity (liver injury) are also documented. Some severe skin reactions can have a delayed onset or prolonged resolution even after use has stopped.


Population-Specific Safety Constraints

The medicine is subject to specific safety constraints for patients with pre-existing conditions. Use should be approached with caution in individuals with severe renal impairment and is generally contraindicated in those with severe hepatic disease or a history of cholestatic jaundice associated with prior macrolide use. The label also notes the potential for exacerbation of Myasthenia Gravis symptoms.

Overdose and Emergency Response

Overdose and when to seek help

This section describes official overdose information strictly based on governmental regulatory documents for Azithromycin (Azitam).


Overdose Scope

Element Official Regulatory Statement
Documented overdose presentations Overdose manifestations are generally similar to those seen at therapeutic doses, including gastrointestinal adverse events and ototoxicity.
Physiological systems affected Cardiovascular system (risk of QT interval prolongation, Torsades de pointes); Auditory system; Gastrointestinal system.
Dose-related or exposure-related factors Associated with exposure to higher than recommended doses. Accidental intravenous overdose has been linked to severe complications.
Population-specific overdose notes Elderly patients may be more susceptible to the development of Torsades de pointes arrhythmias. Infants have demonstrated risk of severe heart block following accidental intravenous overdose.
Emergency-response statements Contact your regional Poison Control Centre immediately. Immediately call emergency services if the individual has collapsed, had a seizure, or has trouble breathing.
When immediate medical help is required Seek immediate medical attention upon suspected overdosage or if severe symptoms are present.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Overdose can lead to potentially fatal irregular heart rhythms.
Regulatory basis Information derived from official FDA Prescribing Information and other government health authority documents.
Overdose-context constraints Treatment is constrained to the use of symptomatic and supportive measures, as no specific antidote is known.

Resulting Overdose Structure

Official overdose statements:

  • Overdosage may result in clinical manifestations similar to adverse reactions seen at normal therapeutic doses, including gastrointestinal adverse events and ototoxicity.
  • Severe or life-threatening outcomes include the risk of Prolongation of the QT interval and developing Torsades de pointes.
  • Management requires the administration of general symptomatic and supportive measures.
  • In cases of suspected overdosage, the official instruction is to seek immediate medical attention and contact a Poison Control Centre.
  • Activated charcoal may be administered to aid in the removal of unabsorbed drug.

Connection to the overall overdose profile (2–4 sentences): Government regulatory documents define the Azithromycin overdose profile by focusing on the exacerbation of common effects and the severe risk of cardiac system compromise. The primary instruction is to seek immediate medical attention and utilize general supportive measures because the regulatory documentation confirms that no specific antidote is known. This structure exclusively addresses documented manifestations, severe outcomes, and regulator-mandated emergency actions.

Therapeutic Uses of Azitam

What Azitam Treats: Main Uses and Benefits

Azitam (Azithromycin) is used to manage infections caused by susceptible bacteria across several key symptomatic domains. The therapeutic application supports the body in addressing the bacterial cause of the illness, which may provide support that helps ease the overall burden of symptoms related to acute and chronic conditions.


Acute Symptom Management

The medication is commonly used across conditions presenting with acute episodes, including bacterial infections of the respiratory tract, such as pneumonia, acute bacterial sinusitis, and acute bacterial exacerbations of chronic bronchitis. It is also considered relevant for localized infections, including acute otitis media (middle ear infection) and certain uncomplicated skin infections. The therapeutic approach is applied in addressing symptom clusters that may become intense or disruptive, such as fever and persistent cough.

Targeted and Preventative Support

Azitam is commonly used to help with addressing specific sexually transmitted infections (STIs) caused by susceptible organisms and is relevant for managing symptoms in specific patient groups for long-term prophylactic support. This includes patients with chronic inflammatory lung diseases to support the management of acute infective episodes. This application supports general well-being during symptomatic phases and contributes to improved comfort by maintaining a sense of stability.


Quick Fact: Supportive Symptom Management

Context Symptom Management Role
Acute Episodes Helps address the underlying bacterial cause of fever and persistent cough.
Localized Discomfort Supports the easing of symptoms associated with ear or skin infections.
Preventative Support Applied to manage the incidence of acute flare-ups in high-risk patients.

Eligibility and Restrictions for Use

Who Can and Cannot Use Azitam?

The eligibility for Azitam (Azithromycin) is determined by regulatory agencies based on established safety profiles and patient health conditions.

Absolute Contraindications Azitam is contraindicated and must not be used by individuals with a known history of hypersensitivity or allergy to Azithromycin, Erythromycin, or any macrolide or ketolide antibacterial drug. Use is also prohibited in patients with a history of cholestatic jaundice or hepatic dysfunction that was previously associated with taking Azitam.

Conditional and Restricted Use Specific caution is required for patients with pre-existing medical conditions. The medicine must be used with caution in individuals with severe renal impairment or severe hepatic impairment. It is also restricted in patients with Myasthenia Gravis due to the potential to exacerbate muscle weakness, and in those with existing prolongation of the QT interval or other proarrhythmic heart conditions.

Age and Reproductive Status Azitam is approved for adults and for pediatric patients who are ge 6 months of age for specific infections. Safety and effectiveness are not established for infants under 6 months. For pregnant patients, use is advised only if clearly needed, and it is generally not recommended during breastfeeding.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Azitam

Interaction Scope

Category Documentation Summary (Strictly Regulatory)
Medicinal product categories with documented interactions QT-prolonging agents (e.g., Antiarrhythmics, certain Antipsychotics), Oral Anticoagulants, P-glycoprotein substrates, CYP3A4 inhibitors, and Antacids (containing aluminum and magnesium).
Specific interacting medicines (if explicitly listed) Quinidine, Amiodarone, Sotalol, Pimozide, Warfarin, Nelfinavir, Atorvastatin, and certain P-gp substrates (e.g., Betrixaban).
Mechanistic basis of interactions (only if stated in label) Officially documented mechanisms include additive pharmacodynamic effects (QT prolongation risk), P-glycoprotein inhibition, and absorption reduction (chelation/pH effects).
Timing-based interaction rules (if applicable) Co-administration with aluminum and magnesium antacids requires a mandatory separation of approximately 2 hours to avoid documented reduction in peak concentration (Cmax).
Population-specific interaction notes (if applicable) Azithromycin exposure is officially noted to be slightly increased in individuals with mild to moderate renal impairment.
Interaction-related restrictions Combination with numerous QT-prolonging agents is formally contraindicated due to documented cardiac risk.

Interaction Classifications (High-Level)

Classification Regulatory Status
Interaction severity classification Contraindicated Combination (for QT-prolonging agents); Significant Interaction Requiring Monitoring (for Warfarin, Nelfinavir); Reduced Cmax Requiring Timing Separation (for antacids).
Regulatory basis Based on official Prescribing Information / Summary of Product Characteristics from government health authorities.
Interaction-context constraints Interaction with food is dependent on the dosage form; peak concentration is increased with food for the capsules and oral suspension.

Resulting Interaction Structure

Official interaction statements: The interaction profile is defined by contraindicated combinations with antiarrhythmics and other QT-prolonging agents due to the additive risk of cardiac arrhythmia. Co-administration with Nelfinavir results in elevated Azithromycin levels, while combination with Warfarin may potentiate anticoagulation effects. Azithromycin’s P-glycoprotein inhibition can increase exposure to certain co-administered drugs. The regulatory assessment classifies interactions based on the need for either strict prohibition, close clinical monitoring, or procedural administration constraints.

Mechanism of Action

Ribosomal Blockade and Inhibition of Growth

The primary mechanism involves Azithromycin acting as a reversible inhibitor, binding to the 23S ribosomal RNA of the 50S subunit to physically obstruct the peptide exit tunnel. This action immediately arrests the synthesis of proteins essential for bacterial function, which physiologically results in the inhibition of microbial proliferation and growth.


️ Modulation of Host Inflammatory Signaling

Azithromycin exerts a distinct mechanistic function by modulating key host inflammatory signaling pathways. It interferes with the activation and downstream signaling of the NF-kappaB transcription factor within immune cells, rather than direct receptor blockade. This action modulates host response by decreasing the production of certain pro-inflammatory mediators at the tissue level, influencing the downstream inflammatory signaling.


Targeted Tissue Accumulation

The final mechanistic domain is the drug's high tissue affinity, where it is actively concentrated inside mobile immune cells, such as phagocytes. These cells act as carriers, transporting high concentrations of the drug directly into infected tissues. This specialized accumulation results in the sustained presence of the active compound, maximizing its availability for ribosomal blockade within infected tissues.

Dosage and Administration Information

How to Use Azitam

Azitam (Azithromycin) is administered via two primary routes: oral and intravenous (IV) infusion. The choice of route and specific dosage form—tablets, oral suspension, or injectable powder—is determined by the clinical scenario.


Standard Dosing and Frequency

The standard adult course generally follows a daily regimen, most commonly for 3 or 5 days. A typical 5-day oral course begins with a 500 mg dose on Day 1, followed by 250 mg once daily on Days 2 through 5. Alternatively, a simplified 3-day course utilizes 500 mg once daily. For specific sexually transmitted infections, a 1,000 mg or 2,000 mg dose may be administered once only.


Administration Context and Specifics

Azitam tablets and the standard oral suspension may be taken with or without food. However, certain formulations, such as the extended-release single-dose oral suspension, are officially instructed to be taken on an empty stomach (at least 1 hour before or 2 hours after a meal). Dosing for pediatric patients is determined based on body weight (mg/kg) and is typically given as an oral suspension.

If the intravenous route is used, the 500 mg powder must be reconstituted and diluted prior to use. The final solution is then infused slowly over a minimum of 60 minutes; it is strictly prohibited to administer the medicine as an IV bolus or an intramuscular injection. If a dose is missed by less than 12 hours, it should be taken immediately and the original schedule resumed.

Recent Clinical Evidence

The Research Landscape: Azitam's Clinical Evaluation

This section introduces the types of high-quality research available, such as randomized controlled trials (RCTs) and regulatory summaries, that form the basis for understanding the research structure for Azitam's evaluation in bacterial infections. Research has examined how Azitam was evaluated against other standard treatments and has monitored outcomes related to systemic or functional status over defined time intervals. These studies help show what has been observed so far regarding the drug's properties.


Evidence for Managing Acute Respiratory Infections

Research examined Azitam for use in conditions associated with acute or disruptive episodes, such as Community-Acquired Pneumonia (CAP). Studies conducted were primarily short-term randomized controlled trials, comparing Azitam to other standard antibiotic regimens. These trials were relevant in assessing short-term or episodic symptom patterns, with outcomes related to physical discomfort like fever and cough, and systemic status.

Studies also explored the use of Azitam in the context of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), conditions characterized by fluctuating or episodic manifestations. Research explored short-term symptom changes in adults experiencing these acute flare-ups, tracking outcomes related to temporary physiological status and measurements of cough or sputum production. While findings describe patterns observed in these short-term trials, data for certain groups remain insufficient, and the evidence base is focused mainly on acute symptom evaluation, meaning there is limited information for long-term outcomes regarding the prevention of subsequent episodes.


Evidence for Localized and Specific Bacterial Infections

Studies explored Azitam for Acute Otitis Media (AOM), mainly in pediatric populations. Research involved RCTs comparing short-course Azitam regimens to longer-course standard antibiotic treatments. These studies monitored patient-reported outcomes describing perceived discomfort and clinical status over defined time intervals. For Uncomplicated Skin and Skin Structure Infections (SSI), research examined Azitam in trials against conventional antibiotics, with outcomes related to physical discomfort, such as measurements of inflammation. It remains important to note that evidence is limited for severe, deep-seated, or complicated skin infections.

Azitam was also studied for certain Sexually Transmitted Infections (STIs), specifically uncomplicated urogenital C. trachomatis. Research explored the use of a single-dose regimen, primarily focusing on microbiological eradication as the key outcome. Findings describe the measured eradication rates for this specific infection as reported in the trials. Data are still emerging regarding comparative evaluation against other regimens, and outcomes for non-urogenital site infections were observed in some studies to be variable.


Evidence Consistency and Areas of Uncertainty

Findings were mixed across the full spectrum of Azitam research, and evidence quality varies across studies. The most consistent uncertainty across all indications relates to long-term effects, as follow-up durations were limited in many trials. For long-term preventative use in chronic lung diseases, the key uncertainty that research is ongoing to address is the potential for antimicrobial resistance to develop over time. This research highlights what is known—and what is still uncertain—and suggests that the results apply only to the populations studied.

Key Studies & References

  1. Drug Record: Azithromycin - NIH National Library of Medicine

Frequently Asked Questions (FAQ)

Common questions about Azitam (FAQ)

Q: How quickly does Azitam typically start working?

Regulatory patient materials suggest that improvement in symptoms is often observed during the first few days of treatment. The time required for an individual to notice a change can vary.


Q: What if I stop taking Azitam suddenly?

Official regulatory documents emphasize that completing the prescribed course is important. Stopping use before the course is finished may result in the infection not being completely treated and could contribute to the development of antibiotic resistance.


Q: What is the difference between Azitam and a traditional [class of drug]?

Azitam belongs to the azalide subclass of macrolide antibiotics. Regulatory documents note that this classification reflects a chemically modified structure that contributes to its prolonged presence in tissues compared to traditional macrolides.


Q: Can Azitam affect my mood or personality?

Official product information describes psychiatric adverse reactions that have been reported, primarily in post-marketing experience. These include observations of agitation, anxiety, aggressive reaction, nervousness, and insomnia (difficulty sleeping). The frequency is noted as generally uncommon or rare.


Q: Is there a generic version of Azitam available?

Yes, the active ingredient in Azitam, Azithromycin, is approved by the FDA and other global authorities and is widely available as a generic medicine.


Q: Can I drive or operate machinery while taking Azitam?

The medicine can cause nervous system side effects such as dizziness and somnolence (drowsiness). Regulatory documents note that these types of effects may affect the ability to drive or safely operate machinery.


Q: What is the risk of dependence or addiction with Azitam?

Official regulatory agencies have not classified Azitam as a controlled substance. The product label does not contain warnings indicating a risk of dependence or addiction.


Q: How long does Azitam stay in your system?

Official pharmacokinetic information indicates that Azitam has a long half-life and is eliminated primarily through the bile, and to a lesser extent, the urine. This long half-life supports its prolonged presence in body tissues.


Q: Can Azitam affect blood pressure?

While the main cardiovascular warnings focus on heart rhythm changes (specifically QT prolongation), hypotension (low blood pressure) has been noted in post-marketing experience. Official information advises caution when used in individuals with pre-existing heart conditions.


Q: Does Azitam cause weight gain or weight loss?

Official documents list anorexia (loss of appetite) as a common side effect. Significant changes in body weight are not listed among the commonly reported adverse reactions in clinical trials.


Q: Are there any long-term health risks associated with Azitam?

Official warnings focus on the risks of acute events like serious cardiac changes and liver injury. For chronic or preventative use, documents also highlight the need to monitor for the potential development of antimicrobial resistance.


Q: Is Azitam safe to use while breastfeeding (informational only)?

Official documents state that the medicine is excreted into human milk. Use during breastfeeding is generally not recommended, though clinical information indicates that effects on the nursing infant are not typically expected due to low systemic levels.


Q: Is it normal to feel [vague side effect, e.g., tired, dizzy] when starting Azitam?

Official product labeling classifies side effects based on how often they were observed in clinical studies. For instance, headache is considered common, while dizziness and fatigue/malaise are listed as less common reactions. The frequency classification describes the likelihood of experiencing these effects.


Q: Does Azitam interact with birth control pills?

Official regulatory documents list specific classes of interacting medicines for which monitoring or dosage adjustments are necessary. Hormonal contraceptives (birth control pills) are not explicitly listed as a drug requiring a specific warning or change in usage due to a known interaction.


Q: How long do you usually have to take Azitam?

The typical duration of use is generally 3 or 5 days for most adult regimens, though this is dependent on the specific infection being treated. A single high dose is used for certain sexually transmitted infections.


Q: Does Azitam interact with commonly used over-the-counter pain relievers?

Official documents list interactions with specific drug classes, such as certain heart medicines and blood thinners. Common over-the-counter pain relievers (like acetaminophen or ibuprofen) are not explicitly listed as drugs requiring mandatory timing separation or clinical monitoring.


Q: Are there any research papers or studies about Azitam I can read?

The information supporting regulatory approval is based on clinical data, primarily randomized controlled trials (RCTs). Regulatory agencies publish summaries of these studies, typically found in the Clinical Pharmacology and Clinical Studies sections of the official product labels.


Q: What kind of monitoring (e.g., blood tests) is sometimes needed while taking Azitam?

Official documents require monitoring for signs of liver injury (hepatotoxicity) and kidney function abnormalities. Specific monitoring of prothrombin time is also specified for individuals taking the blood thinner Warfarin.


Q: What happens if I miss a dose of Azitam?

Official instructions describe the procedure for a missed dose: if a dose is missed, regulatory information indicates that it should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the missed dose is usually skipped, and the regular schedule is resumed. Regulatory documents advise against taking a double dose.


Q: What is the expected duration of effect after taking one dose of Azitam?

Official pharmacokinetic information indicates Azitam has a long half-life, which is the time it takes for the concentration of the medicine to be reduced by half. This long half-life supports its prolonged presence in body tissues.


Q: Why is Azitam only available by prescription?

Azitam is designated as a prescription-only systemic anti-infective. This status reflects the need for professional diagnosis, the presence of serious warnings (such as cardiac risk), and the importance of professional oversight in managing antibiotic resistance.


Q: What official bodies have approved Azitam?

The medicine has been reviewed and approved by major governmental health authorities around the world. These include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), among others.

How should Azitam be stored and disposed of?

Storage and Disposal Requirements for Azithromycin (Azitam)

Official regulatory documents define specific storage and disposal requirements based on the drug's formulation.

Storage Conditions

Tablets and Dry Powder must be kept at controlled room temperature (15 C to 30 C) and protected from excess heat and moisture. The container must remain tightly closed.

Oral Suspension (Reconstituted) must be stored between 5 C and 30 C. The standard suspension must be discarded after 10 days, while the single-dose extended-release suspension must not be refrigerated or frozen and must be discarded after 12 hours.

Handling and Safety

All forms of the medicine must be kept out of the sight and reach of children, and the safety cap must be locked. Unused or expired medication must be thrown away according to regulatory disposal guidelines, such as using a drug take-back program, to ensure safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azitam found in:

A-Z Index: